The present invention relates to the use of helicase-primase inhibitors in a method of treating Alzheimer's Disease (AD). Particularly, the present invention relates to the use of helicase-primase inhibitors in a method of treating AD in a subject that is having HSV-1 infection and is having AD or is having HSV-1 infection and is suspected of having AD. The provided antiviral helicase-primase inhibitors affect the accumulation of the key AD proteins amyloid beta and abnormally phosphorylated tau that occur during HSV-1 infection.
